Nuclear Medicine Equipment Market
Report ID: SQMIG35A3786
Report ID: SQMIG35A3786
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3786 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
92
|Figures:
76
Global Nuclear Medicine Equipment Market size was valued at USD 2.6 Billion in 2024 and is poised to grow from USD 2.8 Billion in 2025 to USD 5.03 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).
The overall shift towards molecular imaging and precision diagnostics is driving the nuclear medicine equipment market growth due to earlier detection and targeted therapy, thus improving outcomes for patients. Nuclear medicine equipment includes gamma cameras as well as SPECT, PET, PET/CT, and PET/MRI hybrid scanners plus cyclotrons and other tools used in radiopharmacy, and the importance of the systems are translating the science of radiopharmaceuticals to actionable clinical decisions. Adoption has rapidly increased over the last 20 years, as oncology and cardiology embraced the use of PET imaging; for example, many cancer centers adopted PET/CT for staging lung and colorectal cancer, while PSMA PET has completely altered the management of prostate cancer, leading to further investment and innovation.
In addition to the continuing growth of diagnostic utilization, one of the critical drivers of global demand for equipment is the growing ecosystem of radiopharmaceuticals, as a reliable supply of isotopes and approval of new isotopes will enable increased use of scanners and justify the acquisition of equipment. When cyclotrons and generator networks reliably provide gallium 68, fluorine 18, and/or lutetium 177, physicians will use the PET imaging protocol and combine diagnostic results with administration of targeted radionuclide therapy, as was the case when significantly increased referrals for lutetium 177 PSMA therapy occurred once PSMA PET was established as the protocol for staging prostate cancer. Increased reimbursement rates for PET and improvements in artificial intelligence (AI) and image analysis to reduce costs per patient and increase their throughput have led hospitals and imaging networks to acquire hybrid systems and expand services in emerging markets.
How is AI Enhancing Diagnostic Accuracy In The Nuclear Medicine Equipment Market?
More and more companies are introducing new features to their existing PET and SPECT equipment so that doctors can obtain enhanced functional image quality and make quicker and more confident decisions. Hospitals have expressed interest in products that allow them to have more diagnostic confidence, easily fit into their current workflow, and produce actual proof of their effectiveness via conferences and vendor-sponsored events.
Recently, GE HealthCare received FDA 510(k) clearance for the Aurora dual, dual-head SPECT/CT imaging system and Clarify DL deep learning-based image reconstruction technology. As a result, there has been an improved ability to see lesions on images due to less time needed for obtaining images, which continues to result in an increase in the number of nuclear imaging equipment sales and higher levels of diagnostic confidence and throughput in the nuclear medical facilities where these systems are in use.
Market snapshot - (2026-2033)
Global Market Size
USD 2.6 Billion
Largest Segment
SPECT Systems
Fastest Growth
PET Systems
Growth Rate
7.6% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global nuclear medicine equipment market is segmented by product type, application, end-user and region. Based on product type, the market is segmented into SPECT Systems, PET Systems, Planar Scintigraphy and Others. Based on application, the market is segmented into Oncology, Cardiology, Neurology and Others. Based on end-user, the market is segmented into Hospitals, Diagnostic Centers and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per nuclear medicine equipment market forecast, PET Systems has a strong market share due to their high level of sensitivity and their ability to provide quantitative data for imaging modalities, which have changed the way we detect and stage disease through nuclear medicine equipment. In addition, the ability of PET systems to work with new and/or advanced radiopharmaceuticals combined with anatomical imaging enhances clinician preferences for accurately locating lesions and monitoring therapy. Investment in both scanner performance/imaging workflow as well as expanding development of tracers creates a cycle of improved performance in which PET is the leading modality for the high value diagnostic and theranostic workflow environment.
As per nuclear medicine equipment market analysis, SPECT Systems is experiencing the greatest growth due to enhanced capabilities, including upgraded detectors and software which have enhanced image quality while also offering very cost-effective solutions. Furthermore, greater availability of tracers along with expanding utilization in cardiologly and neurology has provided a catalyst for greater acceptance of these systems in a wide range of healthcare settings. Increased accessibility is driving replacement cycles and new user purchases offering unique potential for vendors to expand their service and training offerings for their customers.
In the nuclear medicine equipment market, the oncology category is the largest and continues to dominate due to increased use of radionuclide imaging in the diagnosis and treatment of cancer - utilization of cross-modal imaging increases reliance on radionuclide imaging techniques to detect, diagnose, and monitor patient care for both staging cancer and establishing the appropriate treatment options. New methods of treatment with targeted radiopharmaceuticals require more accurate imaging for patient selection and evaluation of treatment response, therefore, healthcare systems are placing a higher priority on obtaining the most advanced scanners and integrating them into their workflow processes. The emphasis placed on clinical practice guidelines and clinical trial requirements are also opening the door for imaging system manufacturers to invest in imaging infrastructure for the development of multidisciplinary oncology imaging capabilities.
As per nuclear medicine equipment market outlook, the cardiology category has been identified as the highest growth potential because of the increasing demand for myocardial perfusion and molecular cardiac imaging. Improvements in tracer chemistry and the introduction of dedicated cardiac detectors have improved diagnostic accuracy as well as the overall workflow of cardiology practices. Additionally, there is an increasing number of clinical practice guidelines that recognize the importance of functional imaging thereby creating a demand for equipment upgrades in cardiology and providing vendors with opportunities to provide additional services.
To get detailed segments analysis, Request a Free Sample Report
North America dominate the global nuclear medicine equipment because there are numerous advanced clinical infrastructures, highly qualified research, and supply reimbursement programs which encourage high usage of diagnostic and therapeutic technologies. In addition, there is a strong presence of manufacturers of leading edge devices and there are also ongoing partnerships between academic medical centers and manufacturers that help speed up the innovation and commercialization processes. Health systems in North America have a strong desire to perform accurate imaging studies and provide patients with molecular therapies. This appetite for innovation directly correlates with growth in the market for current and future imaging devices and tools to deliver radioisotopes to patients. Sufficient money available to capital and supply chains, in addition to the ability to create regulatory, clinical trial, and education networks, create the ability for manufacturers to get new devices into the marketplace as quickly and as efficiently as possible. Further, manufacturers of nuclear medicine equipment provide a great deal of after-sales support which will allow the customer (healthcare provider) to use them to their full potential and purchase equipment that is not only good quality but will provide a long period of time of trouble free operation. As a result, private sector investment in nuclear medicine devices will help drive further demand for public sector usage, thus expanding access to advanced diagnostics using medicine for each patient.
Within the United States, early adopters of the latest imaging technologies, radionuclide therapy systems and radionuclide therapy products make the Nuclear Medicine Equipment Market unique because of the new integrated health care delivery models working together with advanced research activities. Concentrations of specialized sites for use of imaging devices, combined with cooperative agreements between device manufacturers and clinical trial sponsors provide for the development and validation of new products. Existing payment mechanisms, payment rates for the products as well as established distribution systems allow for a more efficient use of resources and assist with installation / maintenance / upgrades of equipment. Competition within the supplier marketplace for these products, combined with the clinician's ability to obtain valuable sources of information regarding the products will drive the future growth within the U.S. marketplace all the way to/from a broader array of geographies.
Within Canada, the Nuclear Medicine Equipment Market is dependent upon having coordinated public health initiatives as well as being able to provide equitable access to advanced diagnostic and therapeutic technologies. Concentrations of expertise within the major population centres in Canada support the adoption of contemporary imaging systems and radiopharmaceutical products. Strong liaisons between the academic hospitals and the regional clinics encourage training, as well as, the standardization of the use of the products. Centralised buying groups and regional service alliances support capital costs as well as manage maintenance networks supporting wider utilisation of the technologies and items of interest on a regional basis.
Rapid expansion of the nuclear medicine equipment market in Europe is driven by coordinated investment in health infrastructure, proactive adoption of molecular imaging, and rising interest in theranostic applications across clinical specialties. Policymakers and health authorities in many countries have supported pathways for integrating advanced diagnostics into care pathways, while cross border research collaborations and pan European academic networks foster knowledge sharing and clinical protocol harmonization. A diverse supplier base, together with targeted funding for radiopharmaceutical production and distribution, has strengthened local capabilities. Robust training programs and multidisciplinary centers promote clinical uptake, and increasing partnerships between hospitals and industry accelerate pilot initiatives that validate clinical and operational value in varied care settings across the region. Greater regulatory convergence and efforts to align reimbursement practices support wider adoption, while growing clinician and patient awareness of precision imaging benefits sustains demand.
Nuclear Medicine Equipment Market in Germany is anchored by strong clinical research centers, a dense hospital network, and advanced radiopharmacy capacity that support widespread adoption of diagnostic and therapeutic platforms. Collaboration between universities, medical centers, and manufacturers accelerates technology validation. Funding mechanisms and regional procurement strategies enable facility upgrades, while technical service providers and logistics networks ensure reliable isotope supply and equipment maintenance, supporting consistent clinical integration across care providers.
Nuclear Medicine Equipment Market in United Kingdom reflects dynamic expansion driven by investments in molecular imaging and growing clinical uptake of theranostics. Partnerships between public bodies and private groups have enabled development of specialized centers and radiopharmacy capacity. Flexible procurement and pilot programs facilitate validation of new systems. Focused training initiatives, cross institutional research collaborations, and active regulatory engagement support clinical integration and broader procurement across tertiary and regional providers.
Nuclear Medicine Equipment Market in France combines academic hospital networks with national programs supporting radiopharmaceutical production. Expertise concentrated in university centers facilitates adoption of advanced imaging and targeted therapies, while regional hospitals benefit from centralized distribution and support arrangements. Collaborative initiatives among clinicians, regulators, and manufacturers streamline protocol adoption and training. Procurement strategies that balance national coordination with regional autonomy enable investments and integration of new equipment across care settings.
Asia Pacific is strengthening its role in the nuclear medicine equipment market through targeted investments in clinical capacity, expansion of local radiopharmaceutical manufacturing, and strategic adoption of emerging imaging and therapy technologies. Regional markets are benefiting from growing hospital infrastructure, expanding specialist training programs, and partnerships with global equipment suppliers that transfer technical expertise and support localization. Government incentives and public private collaborations in several key economies bolster capabilities for isotope production and distribution. Increasing clinical research activity and multi center trials raise local evidence generation, enabling broader clinical acceptance. Enhanced service and maintenance networks, along with growing availability of trained technologists and clinicians, reduce operational barriers and encourage adoption across wider hospital tiers. Together, these developments support more diverse procurement models and cultivate supplier ecosystems capable of responding to both urban referral centers and expanding regional care networks.
Nuclear Medicine Equipment Market in Japan is underpinned by advanced medical centers, strong domestic manufacturing, and extensive nuclear medicine research expertise. Hospitals adopt modern imaging systems and targeted radiotherapeutic approaches supported by local radiopharmacy infrastructure. Collaboration between industry and academia drives device refinement and clinical validation. Well organized maintenance and service channels, combined with targeted training programs, support utilization and adoption across specialty hospitals and regional centers and community clinics.
Nuclear Medicine Equipment Market in South Korea benefits from strong technology adoption, tertiary hospitals, and active industry involvement in imaging innovation. Investments in local radiopharmaceutical manufacturing and distribution networks improve access. Close collaboration among research hospitals, universities, and device suppliers accelerates clinical evaluation and integration of new imaging and therapeutic systems. Robust technical support services and focused workforce training enable deployment across major referral centers and regional hospitals and clinics.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Prevalence Of Chronic Diseases
Advancements In Imaging Technology
High Equipment And Maintenance Costs
Stringent Regulatory And Reimbursement Challenges
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in global nuclear medicine is shaped by aggressive M&A, licensing and manufacturing partnerships and rapid technology innovation focused on radiopharmaceutical pipelines and isotope supply. Recent deals include AstraZeneca's acquisition of Fusion Pharmaceuticals and Novartis' AAA and Endocyte purchases; licensing moves such as Lantheus and GE for PYLARIFY and Curium's AI and reactor partnerships show concrete competitive strategies.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global nuclear medicine equipment market is being propelled by the shift toward molecular imaging and precision diagnostics as a key driver, supported by growing radiopharmaceutical ecosystems that boost scanner utilization. A second driver is rapid adoption of AI and advanced reconstruction algorithms improving image quality and workflow efficiency. A major restraint remains high equipment and maintenance costs that limit uptake in smaller providers and resource constrained regions. North America remains the dominating region due to strong infrastructure, reimbursement and supplier presence. PET systems represent the dominating segment owing to superior sensitivity, quantitative capability and theranostic compatibility.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.6 Billion |
| Market size value in 2033 | USD 5.03 Billion |
| Growth Rate | 7.6% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Nuclear Medicine Equipment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Nuclear Medicine Equipment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Nuclear Medicine Equipment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Nuclear Medicine Equipment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Nuclear Medicine Equipment Market size was valued at USD 2.6 Billion in 2024 and is poised to grow from USD 2.8 Billion in 2025 to USD 5.03 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).
Competitive landscape in global nuclear medicine is shaped by aggressive M&A, licensing and manufacturing partnerships and rapid technology innovation focused on radiopharmaceutical pipelines and isotope supply. Recent deals include AstraZeneca's acquisition of Fusion Pharmaceuticals and Novartis' AAA and Endocyte purchases; licensing moves such as Lantheus and GE for PYLARIFY and Curium's AI and reactor partnerships show concrete competitive strategies. 'Siemens Energy', 'General Electric', 'Philips', 'Hitachi', 'Canon', 'Shimadzu Corporation', 'Digirad', 'Mediso Medical Imaging Systems', 'Surgeons Choice Medical', 'Lantheus Holdings', 'Eckert & Ziegler', 'Cardinal Health', 'Bracco', 'Fujifilm Holdings', 'Spectrum Dynamics Medical', 'CMR Naviscan', 'Milaidhoo', 'Segami Corporation', 'MedEx', 'Nuclisys'
Growing incidence of cancer and cardiovascular conditions has elevated clinical demand for advanced diagnostic and therapeutic nuclear medicine solutions, as these modalities provide unique molecular and functional information that guides personalized treatment decisions. Clinicians increasingly rely on nuclear imaging and radiopharmaceutical therapies to detect disease at earlier stages, monitor treatment response, and tailor interventions, which encourages hospitals and imaging centers to invest in PET, SPECT, and radionuclide therapy infrastructure. This clinical need drives procurement and development of sophisticated equipment across healthcare systems.
Theranostics Integration Growth: Developments in theranostics are catalyzing closer alignment between diagnostic imaging and targeted radionuclide therapies, prompting equipment makers to adapt scanners, detectors and delivery systems for dual diagnostic-therapeutic workflows. Manufacturers, clinical centers and research institutions emphasize modular designs and cross-disciplinary protocols to support personalized treatment planning and monitoring. This shift fosters collaborative ecosystems, drives demand for flexible platforms and enhances patient-centric care pathways by enabling integrated diagnosis, dosimetry and follow-up within unified clinical environments, improving clinical decision-making and operational coordination capacity.
Why does North America Dominate the Global Nuclear Medicine Equipment Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
